CS
Therapeutic Areas
Replimune Pipeline
| Drug | Indication | Phase |
|---|---|---|
| RP1 (vusolimogene odeparepvec) + nivolumab | Advanced Melanoma | Phase 3 |
| RP1 + nivolumab | Non-Melanoma Skin Cancers (Merkel cell carcinoma, Basal cell carcinoma, Angiosarcoma) | Phase 2 |
| RP1 | Skin Cancer in Organ Transplant Recipients | Phase 1b/2 |
| RP2 + nivolumab | Metastatic Uveal Melanoma | Phase 2/3 |
| RP2 + atezolizumab + bevacizumab | Hepatocellular Carcinoma (HCC) | Phase 2 |
| RP2 / RP2 + nivolumab | Various Solid Tumors | Phase 1 |